Case-Based Review

Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review

Volume 10 · Issue 1 Publish Date: August 3, 2022
Full Text PDF
DOI
Derya Yıldırım
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Rıza Can Kardaş
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Burcugul Özkızıltaş
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
İbrahim Vasi
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Hamit Küçük
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Mehmet Akif Öztürk
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Abdurrahman Tufan
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Yıldırım, D., Kardaş, R. C., Özkızıltaş, B., Vasi, İbrahim, Küçük, H., Öztürk, M. A., & Tufan, A. (2022). Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review. European Journal of Rheumatology, 10(1), 29–33. https://doi.org/10.5152/EuJRheum.2022.21180
Full Text Full Text PDF

Abstract

Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases.

Cite this article as: Yıldırım D, Kardaş RC, Özkızıltaş B, et al. Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review. Eur J Rheumatol 2023;10(1):29-33.

Article Info
Published In
Journal European Journal of Rheumatology
Volume / Issue Volume 10 · Issue 1
Pages 29-33
History
Published Online August 3, 2022
Copyright
Affiliations
Derya Yıldırım
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Rıza Can Kardaş
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Burcugul Özkızıltaş
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
İbrahim Vasi
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Hamit Küçük
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Mehmet Akif Öztürk
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Abdurrahman Tufan
Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
Cite this Article
Yıldırım, D., Kardaş, R. C., Özkızıltaş, B., Vasi, İbrahim, Küçük, H., Öztürk, M. A., & Tufan, A. (2022). Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review. European Journal of Rheumatology, 10(1), 29–33. https://doi.org/10.5152/EuJRheum.2022.21180
Share
Outlines